Astrazeneca (AZN) Net Income towards Common Stockholders (2009 - 2026)

Astrazeneca (AZN) has reported Net Income towards Common Stockholders for 18 consecutive years, with $3.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 23.33% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $12.0 billion (up 18.61% YoY), while the FY2025 annual figure was $10.2 billion, up 45.34% from the prior year.
• Net Income towards Common Stockholders came in at $3.1 billion for Q1 2026 at Astrazeneca, up from $2.8 billion in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $4.0 billion in Q1 2025, with the low at -$372.0 million in Q2 2022.
• Average Net Income towards Common Stockholders over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2024.
• The largest YoY upside for Net Income towards Common Stockholders was 33933.61% in 2022 against a maximum downside of 88571428671.43% in 2022.
• Year by year, Net Income towards Common Stockholders stood at $1.7 billion in 2022, then climbed by 4.03% to $1.8 billion in 2023, then slipped by 15.78% to $1.5 billion in 2024, then jumped by 84.67% to $2.8 billion in 2025, then gained by 11.19% to $3.1 billion in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $3.1 billion, $2.8 billion, and $2.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.